Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trulieve Cannabis ( (TSE:TRUL) ) has provided an update.
On February 26, 2026, Trulieve reported fourth quarter and full year 2025 results, posting $1.2 billion in annual revenue, 60% gross margin, and record cash flow from operations of $273 million despite a net loss of $116 million. The company grew branded unit sales, expanded to 233 dispensaries, refinanced debt with new notes due 2030, secured conditional approval for a Texas license, and continued investing in digital tools and new locations, underscoring a strategy of strengthening liquidity and market footprint amid ongoing industry evolution.
The most recent analyst rating on (TSE:TRUL) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on Trulieve Cannabis stock, see the TSE:TRUL Stock Forecast page.
Spark’s Take on TSE:TRUL Stock
According to Spark, TipRanks’ AI Analyst, TSE:TRUL is a Neutral.
Trulieve Cannabis demonstrates strong revenue growth and positive technical momentum, but faces challenges with profitability and valuation. The earnings call provided a balanced view of growth initiatives and existing pressures.
To see Spark’s full report on TSE:TRUL stock, click here.
More about Trulieve Cannabis
Trulieve Cannabis Corp. is a leading U.S. cannabis company focused primarily on retail sales of branded cannabis products, supported by over four million square feet of cultivation and processing capacity. The company operates more than 230 dispensaries nationwide and targets medical and adult-use markets, with a large customer rewards base and expanding presence in key states such as Florida, Ohio and Texas.
Average Trading Volume: 250,289
Technical Sentiment Signal: Sell
Current Market Cap: C$1.67B
For an in-depth examination of TRUL stock, go to TipRanks’ Overview page.